Inställningar

Split view

Short keys for navigating in split view

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Dark Mode

Set dark mode to MFN.se

Sound

Plays a notification sound when new press release is published in the current feed

Intresserad av platformen MFN för nyhetsdistribution?

Onsdag 28 Oktober | 17:16:26 Europe / Stockholm

Svenska | English

Investor Relations

Public Relations

Redeye

Bifogade filer

Mendus Q3 2023 - ADVANCE II survival update at ASH

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

Mendus Q3 2023 - ADVANCE II survival update at ASH

2023-11-09 12:01:00

Redeye provides its comment on Mendus’ Q3 2023 report. We judge that the most critical catalysts for the share will be interim readouts and top-line data from the company’s planned phase II trial in AML maintenance, combining vididencel and oral azacytidine. In the short term, an ADVANCE II survival update at ASH in December might act as a catalyst. We do some housekeeping in our model.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/